CURLF Quote, Financials, Valuation and Earnings

MannKind has a net margin of -19.7% compared to Curaleaf Holdings's net margin of 16.79%. Curaleaf Holdings's return on equity of -21.6% beat MannKind's return on equity of --.

Curaleaf Holdings has a consensus price target of $4.25, signalling upside risk potential of 325%. On the other hand MannKind has an analysts' consensus of $9.38 which suggests that it could grow by 136.74%. Given that Curaleaf Holdings has higher upside potential than MannKind, analysts believe Curaleaf Holdings is more attractive than MannKind.

Curaleaf Holdings has a beta of 0.896, which suggesting that the stock is 10.369% less volatile than S&P 500. In comparison MannKind has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.546%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. MannKind pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $310M, which are larger than MannKind quarterly revenues of $78.4M. Curaleaf Holdings's net income of -$61.1M is lower than MannKind's net income of $13.2M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while MannKind's PE ratio is 39.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.57x versus 3.89x for MannKind. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -19.7% compared to Curaleaf Holdings's net margin of -49.65%. Curaleaf Holdings's return on equity of -21.6% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Curaleaf Holdings has a consensus price target of $4.25, signalling upside risk potential of 325%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Curaleaf Holdings has higher upside potential than NovaBay Pharmaceuticals, analysts believe Curaleaf Holdings is more attractive than NovaBay Pharmaceuticals.

Curaleaf Holdings has a beta of 0.896, which suggesting that the stock is 10.369% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $310M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Curaleaf Holdings's net income of -$61.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.57x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -19.7% compared to Curaleaf Holdings's net margin of -60.08%. Curaleaf Holdings's return on equity of -21.6% beat Sarepta Therapeutics's return on equity of -20.94%.

Curaleaf Holdings has a consensus price target of $4.25, signalling upside risk potential of 325%. On the other hand Sarepta Therapeutics has an analysts' consensus of $44.54 which suggests that it could grow by 144.39%. Given that Curaleaf Holdings has higher upside potential than Sarepta Therapeutics, analysts believe Curaleaf Holdings is more attractive than Sarepta Therapeutics.

Curaleaf Holdings has a beta of 0.896, which suggesting that the stock is 10.369% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $310M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Curaleaf Holdings's net income of -$61.1M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.57x versus 0.91x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -19.7% compared to Curaleaf Holdings's net margin of 23.33%. Curaleaf Holdings's return on equity of -21.6% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Curaleaf Holdings has a consensus price target of $4.25, signalling upside risk potential of 325%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 6.55%. Given that Curaleaf Holdings has higher upside potential than Vertex Pharmaceuticals, analysts believe Curaleaf Holdings is more attractive than Vertex Pharmaceuticals.

Curaleaf Holdings has a beta of 0.896, which suggesting that the stock is 10.369% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

Curaleaf Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Curaleaf Holdings pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Curaleaf Holdings quarterly revenues are $310M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Curaleaf Holdings's net income of -$61.1M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Curaleaf Holdings's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Curaleaf Holdings is 0.57x versus 10.96x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.